Kerusso Capital Management LLC Purchases 3,196 Shares of Amgen Inc. $AMGN

Key Points

• Kerusso Capital Management LLC raised its Amgen stake by 31.8%, buying 3,196 shares to hold 13,259 shares worth $4.34M, about 2.0% of its portfolio and its 20th largest position.
• Amgen beat Q4 estimates with $5.29 EPS (vs. $4.76) and $9.87B revenue (vs. $9.46B), set FY2026 guidance at 21.60–23.00 EPS, and analysts forecast roughly 22.18 EPS for the year.
• The company declared a quarterly dividend of $2.52 (annualized $10.08, ~2.9% yield), while MarketBeat shows a consensus rating of Hold with an average price target of $356.62 amid mixed analyst actions.

Kerusso Capital Management LLC lifted its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 31.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,259 shares of the medical research company's stock after acquiring an additional 3,196 shares during the quarter. Amgen makes up approximately 2.0% of Kerusso Capital Management LLC's portfolio, making the stock its 20th largest position. Kerusso Capital Management LLC's holdings in Amgen were worth $4,340,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Board of the Pension Protection Fund bought a new stake in shares of Amgen in the 4th quarter worth $26,000. Olistico Wealth LLC bought a new stake in shares of Amgen in the 4th quarter worth $33,000. Holos Integrated Wealth LLC bought a new stake in shares of Amgen in the 4th quarter worth $37,000. Cloud Capital Management LLC bought a new stake in shares of Amgen in the 3rd quarter worth $34,000. Finally, Saranac Partners Ltd bought a new stake in shares of Amgen in the 3rd quarter worth $37,000. Institutional investors own 76.50% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Weiss Ratings reissued a "buy (b)" rating on shares of Amgen in a report on Monday, December 29th. Mizuho boosted their price target on shares of Amgen from $280.00 to $295.00 and gave the stock an "outperform" rating in a report on Tuesday, February 10th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Amgen from $285.00 to $295.00 and gave the stock a "hold" rating in a report on Thursday, February 5th. Guggenheim boosted their price target on shares of Amgen from $347.00 to $351.00 and gave the stock a "neutral" rating in a report on Thursday, April 9th. Finally, Jefferies Financial Group assumed coverage on shares of Amgen in a report on Tuesday, March 10th. They issued a "hold" rating and a $350.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Amgen currently has an average rating of "Hold" and a consensus price target of $356.62.

Amgen Price Performance

NASDAQ AMGN opened at $348.62 on Friday. The company has a market cap of $188.14 billion, a PE ratio of 24.50, a price-to-earnings-growth ratio of 3.62 and a beta of 0.47. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The firm's 50-day simple moving average is $361.24 and its two-hundred day simple moving average is $338.80.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company's revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts predict that Amgen Inc. will post 22.18 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen's dividend payout ratio is 70.84%.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Completed early-stage cancer study — Amgen announced completion of a Phase 1/2 MTAP‑null cancer combination study, a pipeline de‑risking milestone that could support long‑term value if follow‑up data are positive. Amgen Marks Key Milestone With Completion of Early MTAP-Null Cancer Combo Study
• Positive Sentiment: Analyst price‑target lift — Guggenheim nudged its price target to $351 (from $347) ahead of earnings, a modest endorsement that may support the stock despite the firm keeping a Neutral rating. Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings
• Neutral Sentiment: CTO retirement and leadership realignment — Amgen announced David M. Reese, M.D. will retire as EVP & Chief Technology Officer effective June 30, with a strategic leadership realignment emphasizing integration of biology and technology; operationally notable but framed as orderly. AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
• Neutral Sentiment: New/maintained Hold coverage — Bernstein and Canaccord Genuity are on Hold for AMGN (Canaccord initiated coverage with a Hold), indicating limited near‑term analyst conviction. Amgen (AMGN) Receives a Hold from Bernstein Canaccord Genuity initiates coverage of Amgen (AMGN) with hold recommendation
• Negative Sentiment: Q1 earnings expected to decline — previews from Zacks/Yahoo suggest Amgen lacks the setup for an earnings beat in the upcoming Q1 report, creating downside risk around the release. Earnings Preview: Amgen (AMGN) Q1 Earnings Expected to Decline
• Negative Sentiment: Insider selling — filings show roughly US$4.1M of insider share sales over the past year, which some investors interpret as a cautionary signal. Amgen Insiders Sell US$4.1m Of Stock, Possibly Signalling Caution

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.